Roles of Sildenafil in Enhancing Drug Sensitivity in Cancer

被引:50
作者
Shi, Zhi [1 ,2 ]
Tiwari, Amit K. [1 ]
Patel, Atish S. [1 ]
Fu, Li-Wu [2 ]
Chen, Zhe-Sheng [1 ]
机构
[1] St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Allied Hlth Profess, Queens, NY USA
[2] Sun Yat Sen Univ, State Key Lab Oncol S China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
基金
美国国家卫生研究院;
关键词
BREAST-TUMOR CELLS; PHASE-I; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; VINCRISTINE RESISTANCE; CYCLIC-NUCLEOTIDES; CYCLOSPORINE-A; COMBINATION; VINBLASTINE; DOXORUBICIN;
D O I
10.1158/0008-5472.CAN-11-0375
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The phenomenon of multidrug resistance (MDR) has decreased the hope for successful cancer chemotherapy. The ATP-binding cassette (ABC) transporter superfamily is the largest transmembrane family. The overexpression of ABC transporters is a major determinant of MDR in cancer cells both in vitro and in vivo. Unfortunately, until recently, most of the strategies used to surmount ABC-transporter-mediated MDR have had limited success. An ideal modulator of MDR would be one that has a low liability to induce toxicity and alter the pharmacokinetic profile of antineoplastic drugs. Sildenafil, an inhibitor of cGMP-specific phosphodiesterase type 5, was found to significantly reverse ABC-transporter-mediated MDR. Our results indicate that sildenafil has differential inhibitory effects on ABC transporters: It significantly decreases the efflux activity of ABCB1 and ABCG2, but has no significant effects on ABCC1. Emerging evidence indicates that sildenafil and other phosphodiesterase type 5 inhibitors may enhance the sensitivity of certain types of cancer to standard chemotherapeutic drugs. Cancer Res; 71(11); 3735-8. (C)2011 AACR.
引用
收藏
页码:3735 / 3738
页数:4
相关论文
共 31 条
  • [1] P-glycoprotein: from genomics to mechanism
    Ambudkar, SV
    Kimchi-Sarfaty, C
    Sauna, ZE
    Gottesman, MM
    [J]. ONCOGENE, 2003, 22 (47) : 7468 - 7485
  • [2] PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE
    BARTLETT, NL
    LUM, BL
    FISHER, GA
    BROPHY, NA
    EHSAN, MN
    HALSEY, J
    SIKIC, BI
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) : 835 - 842
  • [3] Bates S, 2001, CANCER-AM CANCER SOC, V92, P1577, DOI 10.1002/1097-0142(20010915)92:6<1577::AID-CNCR1484>3.0.CO
  • [4] 2-H
  • [5] Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use
    Bender, Andrew T.
    Beavo, Joseph A.
    [J]. PHARMACOLOGICAL REVIEWS, 2006, 58 (03) : 488 - 520
  • [6] BENSON AB, 1985, CANCER TREAT REP, V69, P795
  • [7] PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model
    Black, Keith L.
    Yin, Dali
    Ong, John M.
    Hu, Jinwei
    Konda, Bindu M.
    Wang, Xiao
    Ko, MinHee K.
    Bayan, Jennifer-Ann
    Sacapano, Manuel R.
    Espinoza, Andreas
    Irvin, Dwain K.
    Shu, Yan
    [J]. BRAIN RESEARCH, 2008, 1230 : 290 - 302
  • [8] Transport of cyclic nucleotides and estradiol 17-β-D-glueuronide by multidrug resistance protein 4 -: Resistance to 6-mercaptopurine and 6-thioguanine
    Chen, ZS
    Lee, K
    Kruh, GD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (36) : 33747 - 33754
  • [9] Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction
    Das, Anindita
    Durrant, David
    Mitchell, Clint
    Mayton, Eric
    Hoke, Nicholas N.
    Salloum, Fadi N.
    Park, Margaret A.
    Qureshi, Ian
    Lee, Ray
    Dent, Paul
    Kukreja, Rakesh C.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (42) : 18202 - 18207
  • [10] Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells
    Di, Xu
    Gennings, Chris
    Bear, Harry D.
    Graham, Laura J.
    Sheth, Christopher M.
    White, Kimber L., Jr.
    Gewirtz, David A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (02) : 349 - 360